Off-the-shelf CAR-T shows potential to delay lymphoma relapse in interim Phase 3 results
TL;DR Summary
Allogene Therapeutics reported interim Phase 3 data for its off-the-shelf CAR-T therapy cema-cel in B-cell lymphoma, showing 58% MRD negativity in treated patients versus 16% in those observed with standard care, a result that could delay or prevent cancer relapse in high-risk patients, though the data are preliminary.
- Allogene Therapeutics’ CAR-T treatment eliminates residual cancer cells in B-cell lymphoma patients statnews.com
- Allogene’s off-the-shelf CAR-T erases lingering lymphoma cells in early slice of data Fierce Biotech
- Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics’ MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma Yahoo Finance
- Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform GlobeNewswire
- Off-the-Shelf CAR T Shows 58.3% MRD Clearance in Pretreated LBCL Group CancerNetwork
Reading Insights
Total Reads
0
Unique Readers
27
Time Saved
2 min
vs 3 min read
Condensed
90%
495 → 48 words
Want the full story? Read the original article
Read on statnews.com